Marina Mullins appointed as Vice President – Early Clinical Development at Novotech

In her new role, Mullins will focus on leading Novotech’s early-phase clinical development activities, including trial design, regulatory pathways, and sponsor collaboration. She brings nearly five years of experience at Novotech, where she has held progressively senior leadership roles across therapeutic strategy, client operations, and early clinical development.

Prior to joining Novotech, Mullins worked with the Australasian Leukaemia & Lymphoma Group (ALLG) and Nucleus Network, gaining experience in clinical research environments. Her background also includes frontline pharmacy leadership, contributing to her understanding of clinical operations and patient-focused trial execution.